Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The long-acting Bydureon was linked to fewer gastrointestinal issues but had an increased incidence of injection site reactions
Pharmaceuticals GLP-1 Receptor Agonist Market GLP-1 Receptor Agonist Market Size, Trends, Share, Growth, and Regional Forecast, 2026 to 2033 GLP-1 Receptor Agonist Market by Product (Ozempic, Wegovy, Rybelsus, Victoza, Zepbound, Saxenda, Trulicity, Mounjaro, Others), Indication (Type 2 Diabetes mellitus, Obesity, Others), Route of Administration (Parenteral, Oral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Analysis from 2026 to 2033 December 2025 210 Pages Author : Abhijeet Surwase GLP-1 Receptor Agonist Market Share and Trends Analysis The global GLP-1 receptor agonist market size is estimated to grow from US$ 74.4 billion in 2026 to US$ 232.8 billion by 2033
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA, Rosenstock J
What about normal saline
US$ 24.11
US$ 24.32
US$ 23.45
US$ 21.33
US$ 25.06
US$ 27.27
US$ 22.33
